|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 2 | Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study显示文摘AIM:To investigate efficacy and safety of vildagliptin compared to other oral antidiabetics in clinical practice in Germany.METHODS:In this prospective,open,observational study,patients with type 2 diabetes mellitus(T2DM) previously on oral monotherapy were selected by their treating physician to receive either vildagliptin addon to metformin(cohort 1),vildagliptin+metformin single-pill combination(SPC)(cohort 2)or another dual combination therapy with oral antidiabetic drugs(OADs)(cohort 3).According to routine clinical practice,interim examinations occurred every 3 mo:at baseline,after approximately 3 mo and after approximately 6 mo.Parameters documented in the study included demographic and diagnostic data,history of T2DM,data on diabetes control,vital signs,relevant prior and concomitant medication and disease history.Efficacy was assessed by changes in HbA1c and fasting plasma glucose(FPG)3 mo and 6 mo after initiation of dual combination therapy.Safety was assessed by adverseevent reporting and measurement of specific laboratory values(serum creatinine,total bilirubin,alanine aminotransferase,aspartate aminotransferase,creatine kinase).RESULTS:Between October 2009 and January 2011,a total of 3881 patients were enrolled in this study.Since 47 patients were withdrawn due to protocol violations,3834 patients were included in the statistical analysis.There were no relevant differences between the three cohorts concerning age,body weight and body mass index.Average diabetes duration was approximately 6 years and mean HbA1c was between 7.6%and 7.9% at baseline.Antidiabetic treatment was recorded in 3648 patients.Patients were treated with vildagliptin add-on to metformin(n=603),vildagliptin+metformin(SPC)(n =2198),and other oral OADs including combinations of metformin with sulfonylurea(n=370),with glitazones(n =123),other dipeptidyl peptidase-4 inhibitors(n=99).After 6 mo of treatment,the absolute decrease in HbA1c(mean±SE)was significantly more pronounced in patients receiving vildagliptin add-on to metformin(-0.9% ±0.04%)and vildagliptin+metformin(SPC)(-0.9%± 0.03%)than in patients receiving other OADs(-0.6% ±0.04%;P<0.0001).In addition,significant cohort differences were observed for the improvement in FPG after 6 mo treatment(vildagliptin add-on to metformin:-291 mg/L±18.3 mg/L;vildagliptin+metformin(SPC):-305 mg/L±9.6 mg/L;other antidiabetic drugs:-209 mg/L±14.0 mg/L for(P<0.0001).Moderate decreases in body weight(absolute difference between last control and baseline:mean±SE)were observed for patients in all cohorts(vildagliptin add-on to metformin:-1.4 kg ±0.17 kg;vildagliptin+metformin(SPC):-1.7 kg± 0.09 kg;other OADs:?0.8 kg±0.13 kg).No significant differences in adverse events(AEs)and other safety measures were observed between the cohorts.When performing an additional analysis by age(patients<65 years vs patients≥65 years),there was no relevant difference in the most common AEs between the two age groups and the AE profile was similar to that of the overall patient population.CONCLUSION:Clinical practice confirms that vildagliptin is an effective and well-tolerated treatment in combination with metformin in T2DM patients. | Matthias Blüher Ira Kurz Simone Dannenmaier Markus Dworak | 2012 | World Journal of Diabetes2012，3，9： | 9 |
| 3 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus显示文摘 | Alexander J. Thompson Andrew J. Muir Mark S. Sulkowski Dongliang Ge Jacques Fellay Kevin V. Shianna Thomas Urban Nezam H. Afdhal Ira M. Jacobson Rafael Esteban Fred Poordad Eric J. Lawitz Jonathan McCone Mitchell L. Shiffman Greg W. Galler William M. Lee | 2010 | Gastroenterology2010，，1： | 7 |
| 4 | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection显示文摘 | Nezam Afdhal Stefan Zeuzem Paul Kwo Mario Chojkier Norman Gitlin Massimo Puoti Manuel Romero-Gomez Jean-Pierre Zarski Kosh Agarwal Peter Buggisch Graham R. Foster Norbert Br?u Maria Buti Ira M. Jacobson G. Mani Subramanian Xiao Ding Hongmei Mo Jenny C. Ya | 2014 | The New England Journal of Medicine2014，，： | 6 |
| 5 | A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update显示文摘 | Emmet B. Keeffe Douglas T. Dieterich Steven-Huy B. Han Ira M. Jacobson Paul Martin Eugene R. Schiff Hillel Tobias | 2008 | Clinical Gastroenterology and Hepatology2008，，12： | 5 |
| 6 | 疝环充填式修补与腹股沟疝手术显示文摘 | Alan W.Robbins Ira M.Rutkow 唐健雄 | 2002 | 外科理论与实践2002，7，6： | 5 |
| 7 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 5 |
| 8 | The Incidence of Awareness During Anesthesia: A Multicenter United States Study显示文摘 | Peter S. Sebel T. Andrew Bowdle Mohamed M. Ghoneim Ira J. Rampil Roger E. Padilla Tong Joo Gan Karen B. Domino | 2004 | Anesthesia & Analgesia2004，，3： | 3 |
| 9 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 10 | Macrophages in the Pathogenesis of Atherosclerosis显示文摘 | Kathryn J. Moore Ira Tabas | 2011 | Cell2011，，3： | 3 |
| 11 | A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update显示文摘 | Emmet B. Keeffe Douglas T. Dieterich Steven–Huy B. Han Ira M. Jacobson Paul Martin Eugene R. Schiff Hillel Tobias Teresa L. Wright | 2006 | Clinical Gastroenterology and Hepatology2006，，8： | 2 |
| 12 | Long-Term Outcomes for Patients with Post–Liver Transplant Anastomotic Biliary Strictures Treated by Endoscopic Stent Placement显示文摘 | Joseph Morelli Hugh E Mulcahy Ira R Willner John T Cunningham Peter Draganov | 2003 | Gastrointestinal Endoscopy2003，，3： | 2 |
| 13 | The temporal price relationship between S&P 500 futures prices and the S&P 500 index显示文摘 | Kawaller Ira G Paul D Koch Timothy W Koch | 1987 | Journal of Finance1987，5，： | 2 |
| 14 | Laparoscopicvs. open abdominoperineal resection for cancer显示文摘 | James W. Fleshman M.D. Steven D. Wexner M.D. Mehran Anvari Ph.D M.D. Jean-Francois LaTulippe M.D. Elisa H. Birnbaum M.D. Ira J. Kodner M.D. Thomas E. Read M.D. Juan J. Nogueras M.D. Eric G. Weiss M.D | 1999 | Diseases of the Colon & Rectum1999，，7： | 2 |
| 15 | Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver显示文摘 | Ira M. Jacobson Patrice Cacoub Luigino Dal Maso Stephen A. Harrison Zobair M. Younossi | 2010 | Clinical Gastroenterology and Hepatology2010，，12： | 2 |
| 16 | Anal cancer and intraepithelial neoplasia screening: A review显示文摘This review focuses on the early diagnosis of anal cancerand its precursor lesions through routine screening. A number of risk-stratification strategies as well as screening techniques have been suggested, and currently little consensus exists among national societies. Much of the current clinical rationale for the prevention of anal cancer derives from the similar tumor biology of cervical cancer and the successful use of routine screening to identify cervical cancer and its precursors early in the disease process. It is thought that such a strategy of identifying early anal intraepithelial neoplasia will reduce the incidence of invasive anal cancer. The low prevalence of anal cancer in the general population prevents the use of routine screening. However, routine screening of selected populations has been shown to be a more promising strategy. Potential screening modalities include digital anorectal exam, anal Papanicolaou testing, human papilloma virus co-testing, and high-resolution anoscopy. Additional research associating high-grade dysplasia treatment with anal cancer prevention as well as direct comparisons of screening regimens is necessary to develop further anal cancer screening recommendations. | Ira L Leeds Sandy H Fang | 2016 | World Journal of Gastrointestinal Surgery2016，8，1： | 2 |
| 17 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 2 |
| 18 | Prediction of Esophageal Varices in Patients With Cirrhosis显示文摘 | Ravi Madhotra Hugh E. Mulcahy Ira Willner Adrian Reuben | 2002 | Journal of Clinical Gastroenterology2002，，1： | 2 |
| 19 | Impact of experience with a retrograde-viewing device on adenoma detection rates and withdrawal times during colonoscopy: the Third Eye Retroscope study group显示文摘 | Daniel C. DeMarco Elizabeth Odstrcil Luis F. Lara David Bass Chase Herdman Timothy Kinney Kapil Gupta Leon Wolf Thomas Dewar Thomas M. Deas Manoj K. Mehta M. Badar Anwer Randall Pellish J. Kent Hamilton Daniel Polter K. Gautham Reddy Ira Hanan | 2010 | Gastrointestinal Endoscopy2010，，3： | 2 |
| 20 | Mechanisms of ER Stress-Induced Apoptosis in Atherosclerosis显示文摘 | Christopher M. Scull Ira Tabas | 2011 | Arteriosclerosis Thrombosis and Vascular Biology2011，，12： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员